TN2016000239A1 - Quinazolin-thf-amines as pde1 inhibitors. - Google Patents

Quinazolin-thf-amines as pde1 inhibitors.

Info

Publication number
TN2016000239A1
TN2016000239A1 TN2016000239A TN2016000239A TN2016000239A1 TN 2016000239 A1 TN2016000239 A1 TN 2016000239A1 TN 2016000239 A TN2016000239 A TN 2016000239A TN 2016000239 A TN2016000239 A TN 2016000239A TN 2016000239 A1 TN2016000239 A1 TN 2016000239A1
Authority
TN
Tunisia
Prior art keywords
quinazolin
thf
amines
pde1 inhibitors
pde1
Prior art date
Application number
TN2016000239A
Other languages
English (en)
Inventor
Jan Kehler
Morten Langgård
Lars Kyhn Rasmussen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of TN2016000239A1 publication Critical patent/TN2016000239A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TN2016000239A 2013-12-19 2014-12-18 Quinazolin-thf-amines as pde1 inhibitors. TN2016000239A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201300707 2013-12-19
DKPA201400249 2014-05-06
PCT/EP2014/078475 WO2015091805A1 (en) 2013-12-19 2014-12-18 Quinazolin-thf-amines as pde1 inhibitors

Publications (1)

Publication Number Publication Date
TN2016000239A1 true TN2016000239A1 (en) 2017-10-06

Family

ID=52350066

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2016000239A TN2016000239A1 (en) 2013-12-19 2014-12-18 Quinazolin-thf-amines as pde1 inhibitors.

Country Status (26)

Country Link
US (3) US20150175584A1 (es)
EP (1) EP3083607B1 (es)
JP (1) JP6419832B2 (es)
KR (1) KR20160098269A (es)
CN (1) CN105829300B (es)
AP (1) AP2016009293A0 (es)
AU (1) AU2014368601B2 (es)
BR (1) BR112016013946A8 (es)
CA (1) CA2933299A1 (es)
CL (1) CL2016001488A1 (es)
CR (1) CR20160282A (es)
DO (1) DOP2016000152A (es)
EA (1) EA201691108A1 (es)
EC (1) ECSP16061208A (es)
ES (1) ES2728079T3 (es)
GE (1) GEP201706764B (es)
IL (1) IL246230A0 (es)
MX (1) MX2016007945A (es)
PE (1) PE20160855A1 (es)
PH (1) PH12016501173A1 (es)
RU (1) RU2016125315A (es)
SG (1) SG11201604936TA (es)
SV (1) SV2016005220A (es)
TN (1) TN2016000239A1 (es)
TW (1) TW201609713A (es)
WO (1) WO2015091805A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609713A (zh) * 2013-12-19 2016-03-16 H 朗德貝克公司 作爲pde1抑制劑之喹唑啉-thf-胺
DK3126354T3 (da) * 2014-04-04 2020-03-09 H Lundbeck As Halogenerede quinazolin-thf-aminer som pde1-inhibitorer
TWI729109B (zh) * 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JP7111720B2 (ja) 2016-12-28 2022-08-02 ダート・ニューロサイエンス・エルエルシー Pde2阻害剤としての置換ピラゾロピリミジノン化合物
CA3120971A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002324846B2 (en) * 2001-08-31 2007-05-10 Childrens Hospital Medical Center Phosphodiesterase activity and regulation of phosphodiesterase 1-B-mediated signaling in brain
ZA200507228B (en) * 2003-04-01 2007-03-28 Applied Research Systems Inhibitors of phosphodiesterases in infertility
EP1751159A2 (en) * 2004-04-28 2007-02-14 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
US20070093515A1 (en) 2005-08-16 2007-04-26 Arrington Mark P Phosphodiesterase 10 inhibitors
EP1996587A1 (en) * 2006-02-23 2008-12-03 Pfizer Products Incorporated Substituted quinazolines as pde10 inhibitors
US20110190373A1 (en) * 2008-05-05 2011-08-04 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
WO2010132127A1 (en) * 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
EP2480537A1 (en) * 2009-09-24 2012-08-01 Basf Se Aminoquinazoline compounds for combating invertebrate pests
TW201609713A (zh) 2013-12-19 2016-03-16 H 朗德貝克公司 作爲pde1抑制劑之喹唑啉-thf-胺

Also Published As

Publication number Publication date
US20170267664A1 (en) 2017-09-21
AU2014368601B2 (en) 2018-07-05
AU2014368601A1 (en) 2016-06-30
CL2016001488A1 (es) 2016-12-09
WO2015091805A1 (en) 2015-06-25
PE20160855A1 (es) 2016-09-23
GEP201706764B (en) 2017-10-25
JP2017500339A (ja) 2017-01-05
BR112016013946A2 (pt) 2017-08-08
EP3083607B1 (en) 2019-04-24
SG11201604936TA (en) 2016-07-28
TW201609713A (zh) 2016-03-16
CN105829300A (zh) 2016-08-03
RU2016125315A (ru) 2018-01-24
IL246230A0 (en) 2016-08-02
MX2016007945A (es) 2016-10-12
CN105829300B (zh) 2019-03-15
PH12016501173A1 (en) 2016-08-15
CA2933299A1 (en) 2015-06-25
US9701665B2 (en) 2017-07-11
US20150175584A1 (en) 2015-06-25
ECSP16061208A (es) 2017-08-31
JP6419832B2 (ja) 2018-11-07
KR20160098269A (ko) 2016-08-18
SV2016005220A (es) 2016-11-30
EP3083607A1 (en) 2016-10-26
EA201691108A1 (ru) 2016-09-30
AP2016009293A0 (en) 2016-06-30
ES2728079T3 (es) 2019-10-22
US20160318910A1 (en) 2016-11-03
BR112016013946A8 (pt) 2018-01-30
CR20160282A (es) 2016-09-06
DOP2016000152A (es) 2016-09-30
US10030007B2 (en) 2018-07-24

Similar Documents

Publication Publication Date Title
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
PH12017501990A1 (en) Imidazopyrazinones as pde1 inhibitors
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
PH12016501938A1 (en) Halogenated quinazolin-thf-amines as pde1 inhibitors
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation